1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Celyad Oncology SA
  6. News
  7. Summary
    CYAD   BE0974260896

CELYAD ONCOLOGY SA

(CYAD)
  Report
Real-time Euronext Bruxelles  -  05/16 03:54:36 am EDT
1.630 EUR   -0.61%
05/06Celyad Oncology SA Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/05CELYAD ONCOLOGY SA : Proxy Statments
CO
05/05CELYAD ONCOLOGY SA : 1st quarter results
CO
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Celyad Oncology Announces January 2022 Conference Schedule

12/22/2021 | 01:00am EDT

MONT-SAINT-GUIBERT, Belgium, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company plans to participate virtually in the following conference in January 2022:

H.C. Wainwright BioConnect 2022 Conference
Dates: Monday, January 10 to Thursday, January 13, 2022
Presentation: On-demand starting January 10, 7 a.m. ET / 1 p.m. CET
Presenter: Filippo Petti, CEO

About Celyad Oncology SA

Celyad Oncology SA is a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company is developing a pipeline of allogeneic (off-the-shelf) and autologous (personalized) CAR T cell therapy candidates for the treatment of both hematological malignancies and solid tumors. Celyad Oncology was founded in 2007 and is based in Mont-Saint-Guibert, Belgium and New York, NY. The Company has received funding from the Walloon Region (Belgium) to support the advancement of its CAR T cell therapy programs. For more information, please visit www.celyad.com.

Forward-looking statements

This release may contain forward-looking statements, within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding the clinical activity and safety and tolerability of CYAD-211 and expectations regarding enrollment and the announcement of additional clinical data, and the clinical activity and safety and tolerability of the CYAD-02 and CYAD-101 programs. Forward-looking statements may involve known and unknown risks and uncertainties which might cause actual results, financial condition, performance or achievements of Celyad Oncology to differ materially from those expressed or implied by such forward-looking statements. Such risk and uncertainty can be found in Celyad Oncology’s U.S. Securities and Exchange Commission (SEC) filings and reports, including in the latest Annual Report on Form 20-F filed with the SEC and subsequent filings and reports by Celyad Oncology. These forward-looking statements speak only as of the date of publication of this document and Celyad Oncology’s actual results may differ materially from those expressed or implied by these forward-looking statements. Celyad Oncology expressly disclaims any obligation to update any such forward-looking statements in this document to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, unless required by law or regulation.

Investor and Media Contacts: 
  
Sara ZelkovicDaniel Ferry
Communications & Investor Relations DirectorManaging Director
Celyad OncologyLifeSci Advisors, LLC
investors@celyad.comdaniel@lifesciadvisors.com

 


Primary Logo

Source: Celyad Oncology SA

2021 GlobeNewswire, Inc., source Press Releases

All news about CELYAD ONCOLOGY SA
05/06Celyad Oncology SA Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/05CELYAD ONCOLOGY SA : Proxy Statments
CO
05/05CELYAD ONCOLOGY SA : 1st quarter results
CO
04/01CELYAD ONCOLOGY SA : Ordinary general shareholder meeting
CO
03/25TRANSCRIPT : Celyad Oncology SA, 2021 Earnings Call, Mar 25, 2022
CI
03/25CELYAD ONCOLOGY : Reports Full Year 2021 Financial Results and Recent Business Highlights ..
PU
03/25CELYAD ONCOLOGY : Letter to Shareholders – March 2022
PU
03/24Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2021
CI
03/24Celyad Oncology Reports Full Year 2021 Financial Results and Recent Business Highlights
AQ
03/24CELYAD ONCOLOGY SA : Annual results
CO
More news
Analyst Recommendations on CELYAD ONCOLOGY SA
More recommendations
Financials
Sales 2022 7,27 M 7,57 M 7,57 M
Net income 2022 -34,7 M -36,2 M -36,2 M
Net cash 2022 9,67 M 10,1 M 10,1 M
P/E ratio 2022 -1,21x
Yield 2022 -
Capitalization 37,1 M 38,6 M 38,6 M
EV / Sales 2022 3,77x
Capi. / Sales 2023 4,19x
Nbr of Employees 98
Free-Float 60,2%
Chart CELYAD ONCOLOGY SA
Duration : Period :
Celyad Oncology SA Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CELYAD ONCOLOGY SA
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 1,64 €
Average target price 11,00 €
Spread / Average Target 571%
EPS Revisions
Managers and Directors
Filippo Joseph Petti Director, Chief Executive & Financial Officer
Michel E. Lussier Chairman
Frederic Lehmann VP-Clinical Development & Medical Affairs
David Gilham Chief Scientific Officer
Peggy Sotiropoulou Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CELYAD ONCOLOGY SA-53.34%39
MODERNA, INC.-45.70%54 855
LONZA GROUP AG-27.63%40 862
IQVIA HOLDINGS INC.-26.03%39 504
SEAGEN INC.-12.27%24 966
ICON PUBLIC LIMITED COMPANY-31.87%17 153